Giacomo Cartenì

8.4k total citations · 1 hit paper
110 papers, 3.2k citations indexed

About

Giacomo Cartenì is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Giacomo Cartenì has authored 110 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Pulmonary and Respiratory Medicine, 59 papers in Oncology and 29 papers in Cancer Research. Recurrent topics in Giacomo Cartenì's work include Renal cell carcinoma treatment (37 papers), Cancer Genomics and Diagnostics (23 papers) and Cancer Treatment and Pharmacology (22 papers). Giacomo Cartenì is often cited by papers focused on Renal cell carcinoma treatment (37 papers), Cancer Genomics and Diagnostics (23 papers) and Cancer Treatment and Pharmacology (22 papers). Giacomo Cartenì collaborates with scholars based in Italy, United States and United Kingdom. Giacomo Cartenì's co-authors include Luigi Manzione, Vittorio Gebbia, Evaristo Maiello, Francesco Giuliani, S. Romito, Sabino De Placido, Salvatore Siena, Giuseppe Colucci, Giuseppe Di Lorenzo and G Paoletti and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Endocrinology.

In The Last Decade

Giacomo Cartenì

104 papers receiving 3.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia Meridionale

2005 586 citations Giacomo Cartenì, Giuseppe Pezzella et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Giacomo Cartenì Italy	27	1.7k	1.4k	864	648	521	110	3.2k
Luigi Manzione Italy	29	2.4k 1.4×	1.3k 0.9×	637 0.7×	386 0.6×	394 0.8×	88	3.4k
Kazuhiro Sakamoto Japan	26	1.4k 0.8×	1.1k 0.7×	1.2k 1.3×	466 0.7×	412 0.8×	325	3.0k
Roberto Petrioli Italy	28	1.6k 0.9×	1.2k 0.9×	855 1.0×	508 0.8×	407 0.8×	135	3.1k
Gary Richardson Australia	19	2.6k 1.5×	1.2k 0.9×	478 0.6×	734 1.1×	429 0.8×	110	3.8k
Ralph Levitt United States	27	2.1k 1.2×	892 0.6×	682 0.8×	670 1.0×	273 0.5×	67	3.6k
P. Murawa Poland	16	3.0k 1.7×	1.2k 0.8×	770 0.9×	890 1.4×	1.1k 2.1×	47	4.1k
Elizabeth Poplin United States	24	2.2k 1.3×	1.2k 0.8×	721 0.8×	681 1.1×	485 0.9×	80	3.2k
Seong Hyeon Yun South Korea	37	3.5k 2.0×	1.0k 0.7×	2.2k 2.6×	406 0.6×	362 0.7×	207	4.5k
Jorge Aparicio Spain	29	3.0k 1.7×	1.4k 1.0×	1.7k 2.0×	551 0.9×	336 0.6×	147	4.3k
Jorge Barriuso United Kingdom	34	2.4k 1.4×	908 0.6×	1.1k 1.2×	979 1.5×	815 1.6×	137	4.0k

Countries citing papers authored by Giacomo Cartenì

Since Specialization

Citations

This map shows the geographic impact of Giacomo Cartenì's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giacomo Cartenì with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giacomo Cartenì more than expected).

Fields of papers citing papers by Giacomo Cartenì

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giacomo Cartenì. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giacomo Cartenì. The network helps show where Giacomo Cartenì may publish in the future.

Co-authorship network of co-authors of Giacomo Cartenì

This figure shows the co-authorship network connecting the top 25 collaborators of Giacomo Cartenì. A scholar is included among the top collaborators of Giacomo Cartenì based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giacomo Cartenì. Giacomo Cartenì is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guadalupi, Valentina, Giacomo Cartenì, Roberto Iacovelli, et al.. (2021). Second-line treatment in renal cell carcinoma: clinical experience and decision making. Therapeutic Advances in Urology. 13. 3613369366–3613369366. 3 indexed citations

Vitale, Maria Giuseppa, Anna Crispo, Francesco Habetswallner, et al.. (2020). ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-Zeolite to Prevent Chemotherapy-Induced Side Effects, in Particular, Peripheral Neuropathy. Molecules. 25(10). 2297–2297. 11 indexed citations

Raimondi, Alessandra, Raffaele Ratta, Elena Verzoni, et al.. (2019). Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. Clinical Genitourinary Cancer. 17(4). 291–298. 24 indexed citations

Lorenzo, Giuseppe Di, Guru Sonpavde, Gregory R. Pond, et al.. (2017). Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. European Urology Focus. 4(6). 874–879. 22 indexed citations

Migliorino, M.R., Alain Gelibter, Francesco Grossi, et al.. (2017). Use of nivolumab in elderly patients with advanced non-squamous NSCLC: Results from the Italian expanded access program (EAP). Annals of Oncology. 28. v471–v471. 6 indexed citations

Russo, Giuseppe Lo, Lucio Crinò, Domenico Galetta, et al.. (2017). MA14.06 Nivolumab in Never Smoker Patients with Advanced Squamous NSCLC: Results from the Italian Expanded Access Programme (EAP). Journal of Thoracic Oncology. 12(1). S424–S425. 1 indexed citations

Ravaud, Alain, Robert J. Motzer, Hardev Pandha, et al.. (2016). genitourinary tumours, non prostate Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC). Annals of Oncology. 27. vi565–vi565. 1 indexed citations

Ciardiello, Fortunato, Lisa Salvatore, Stefano Cascinu, et al.. (2016). Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase 3b CONSIGN trial. Annals of Oncology. 27. iv44–iv44.

Rizzo, Mimma, Gaetano Facchini, Giuseppe Di Lorenzo, et al.. (2014). Everolimus as second-line therapy for metastatic renal cell carcinoma: a ‘real-life’ study. Future Oncology. 11(2). 219–224. 7 indexed citations

10.

Brandes, Alba A., Gaetano Finocchiaro, Vittorina Zagonel, et al.. (2014). AT-11 * FINAL RESULTS FROM THE RANDOMIZED PHASE II TRIAL AVAREG (ML25739) WITH BEVACIZUMAB (BEV) OR FOTEMUSTINE (FTM) IN RECURRENT GBM. Neuro-Oncology. 16(suppl 5). v10–v10. 4 indexed citations

11.

Riccardi, Ferdinando, et al.. (2014). Pancreatic solitary and synchronous metastasis from breast cancer: a case report and systematic review of controversies in diagnosis and treatment. World Journal of Surgical Oncology. 12(1). 2–2. 17 indexed citations

12.

Laterza, Maria Maddalena, et al.. (2013). Gefitinib in non-small cell lung carcinoma: a case report of an unusual side effect and complete response in advanced disease.. PubMed. 99(1). 3e–5e. 3 indexed citations

13.

Bracarda, Sergio, Paolo Marchetti, Donatello Gasparro, et al.. (2013). Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP).. Journal of Clinical Oncology. 31(6_suppl). 189–189. 2 indexed citations

14.

Gore, Martin, Hariharan Subramanian, Camillo Porta, et al.. (2010). Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer. 117(3). 501–509. 105 indexed citations

15.

Lorenzo, Giuseppe Di, Riccardo Autorino, Giacomo Cartenì, et al.. (2009). Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Annals of Oncology. 20(9). 1535–1542. 169 indexed citations

16.

Tan, E.H., Janusz Rolski, Tomasz Grodzki, et al.. (2009). Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Annals of Oncology. 20(7). 1249–1256. 56 indexed citations

17.

Lorenzo, Giuseppe Di, Giacomo Cartenì, Riccardo Autorino, et al.. (2009). Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer. Journal of Clinical Oncology. 27(27). 4469–4474. 102 indexed citations

18.

Cartenì, Giacomo, Laura Giannetta, G. Ucci, et al.. (2007). Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly. Supportive Care in Cancer. 15(9). 1057–1066. 12 indexed citations

19.

Caponigro, Francesco, Pasquale Comella, Maria Biglietto, et al.. (1999). A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5‐fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck. Cancer. 85(4). 952–959. 1 indexed citations

20.

Biglietto, Maria, Corrado Gallo Stampino, Giuseppe Palmieri, et al.. (1995). Dose–Finding Study of 5’-Deoxy-5-Fluorouridine in Combination with Fixed Doses of Cisplatin and <i>L</i>-Folinic Acid for the Treatment of Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck. Oncology. 52(4). 326–330. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact